What we have found is not so relevant to ICSI.

What we have found is not so relevant to ICSI, where injected injected into the egg, but for those treatments where we are trying the best quality sperm are getting for intrauterine insemination.

He said. Our data challenge the role of abstinence in male infertility treatments.

ON N GENE RESEARCH LABORATORYN – Gene Research Laboratories, in New York City, is a biopharmaceutical company developing drugs to treat insulin resistance and other metabolic disorders. The company has of drugs that of drugs that function through stimulation of the heat shock protein and nitric oxide synthase systems, and the subsequent insulin sensitizing effect of multiple downstream signaling pathways including improved mitochondrial function is mediated. Is located in Budapest, more information, including the poster presented at the ADA conference, please visit.

Placebo controlled study Laboratories announces positive Phase II results with BGP-15 Insulin sensitizerN – Gene Research Laboratories, a privately held biopharmaceutical company developing products to treat insulin resistance, today announced positive Phase II data for BGP-15, a novel insulin sensitizer.The products OnlineFirst and publishes in its October issue of The Lancet Oncology reported that a dexamethasone based treatment reduces the risk of recurrence and improves the rate of healing in child with acute lymphatic leukemia . This can without use of radiation and some the cranial often used chemotherapy be achieved, therefore, minimizing the risk of unnecessary side effects. This highly effective treatment gives results the same by best international records.

Even of overall survival had in ALL-9 protocol, 90 % of patients of NHR and 78 % for HR patients. The authors write in the conclusion: ‘The findings to NHR patients with a large cumulative doses of dexamethasone and vincristin have been achieved, however without using anthracyclines, etoposide, cyclophosphamide or irradiation of the head, therefore, minimizing risk of adverse events? the 5-year event-free survival from 72 percent the ALL-9 HR group without using cranial irradiation and with restricted used of anthracyclines and cyclophosphamide are result of outcome in that group patients.